epoetin alfa
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms, Rectal Neoplasms
Trial Timeline
Dec 1, 2001 → Dec 1, 2003
NCT ID
NCT00036400About epoetin alfa
epoetin alfa is a phase 3 stage product being developed by Johnson & Johnson for Stomach Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00036400. Target conditions include Stomach Neoplasms, Rectal Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00270010 | Phase 2 | Completed |
| NCT00266617 | Phase 2 | Completed |
| NCT00002022 | Pre-clinical | Completed |
| NCT00269984 | Phase 2 | Completed |
| NCT00269945 | Phase 2 | Completed |
| NCT00270114 | Phase 2/3 | Completed |
| NCT00446602 | Phase 2 | Withdrawn |
| NCT00270179 | Phase 3 | Completed |
| NCT00269997 | Phase 2 | Completed |
| NCT00270023 | Phase 2/3 | Completed |
| NCT00270270 | Phase 2 | Completed |
| NCT00337935 | Phase 2 | Completed |
| NCT00306267 | Phase 2 | Terminated |
| NCT00641589 | Phase 1 | Completed |
| NCT00246298 | Phase 2 | Terminated |
| NCT00212875 | Phase 2 | Completed |
| NCT00236405 | Phase 2 | Terminated |
| NCT00240734 | Phase 2 | Terminated |
| NCT00210587 | Phase 3 | Completed |
| NCT00236678 | Phase 2 | Terminated |
Competing Products
20 competing products in Stomach Neoplasms